van den Ouweland Ans M W, van Minkelen Rick, Bolman Galhana M, Wouters Cokkie H, Becht-Noordermeer Cindy, Deelen Wout H, Deelen-Manders J Marianne C, Ippel Elly P F, Saris Jasper, Halley Dicky J J
Department of Clinical Genetics, Erasmus Medical Center, Rotterdam, The Netherlands.
Genet Test Mol Biomarkers. 2012 Sep;16(9):1015-8. doi: 10.1089/gtmb.2012.0012. Epub 2012 Jun 12.
Most patients (98%) with Friedreich's ataxia (FRDA) are homozygous for the GAA repeat expansion in FXN. Only a few compound heterozygous patients with an expanded repeat on one allele and a point mutation or an intragenic FXN deletion on the other allele are described. In a minority of the patients only a heterozygous pattern of the repeat expansion can be detected. Using array analysis after GAA repeat expansion testing, we identified a FRDA patient who is compound heterozygous for an expanded GAA repeat and a complete FXN deletion. Since not only repeat expansions and point mutations, but also large rearrangements can be the underlying cause of FRDA, a quantitative test should also be performed in case a patient shows only one allele with an expanded GAA repeat in FXN.
大多数弗里德赖希共济失调(FRDA)患者(98%)在FXN基因中GAA重复序列扩增方面是纯合子。仅有少数报道称存在复合杂合子患者,其一个等位基因上有重复序列扩增,另一个等位基因上有一个点突变或基因内FXN缺失。在少数患者中,仅能检测到重复序列扩增的杂合子模式。在进行GAA重复序列扩增检测后使用阵列分析,我们鉴定出一名FRDA患者,其为GAA重复序列扩增和完全FXN缺失的复合杂合子。由于不仅重复序列扩增和点突变,而且大的重排都可能是FRDA的潜在病因,因此,如果患者在FXN中仅显示一个带有GAA重复序列扩增的等位基因,也应进行定量检测。